MY169670A - Combinations of a pyrimidine containing nnrti with rt inhibitors - Google Patents

Combinations of a pyrimidine containing nnrti with rt inhibitors

Info

Publication number
MY169670A
MY169670A MYPI20043578A MYPI20043578A MY169670A MY 169670 A MY169670 A MY 169670A MY PI20043578 A MYPI20043578 A MY PI20043578A MY PI20043578 A MYPI20043578 A MY PI20043578A MY 169670 A MY169670 A MY 169670A
Authority
MY
Malaysia
Prior art keywords
combinations
inhibitors
pyrimidine containing
nnrti
containing nnrti
Prior art date
Application number
MYPI20043578A
Other languages
English (en)
Inventor
Paul Stoffels
Original Assignee
Tibotec Pharm Ltd
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY169670(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharm Ltd, Janssen Sciences Ireland Uc filed Critical Tibotec Pharm Ltd
Priority to CNA200580038025XA priority Critical patent/CN101056673A/zh
Priority to HRP20120499TT priority patent/HRP20120499T1/hr
Priority to BRPI0514871-5A priority patent/BRPI0514871A/pt
Priority to CN201510012919.7A priority patent/CN104586850A/zh
Priority to EP05108086.9A priority patent/EP1632232B3/en
Priority to SG200905799-3A priority patent/SG155885A1/en
Priority to PT05108086T priority patent/PT1632232E/pt
Priority to MX2007002595A priority patent/MX2007002595A/es
Priority to ES05779369T priority patent/ES2384715T3/es
Priority to KR1020077006837A priority patent/KR101284361B1/ko
Priority to US11/219,163 priority patent/US7638522B2/en
Priority to PCT/EP2005/054341 priority patent/WO2006024667A1/en
Priority to MEP-2011-144A priority patent/ME01246B/me
Priority to JP2007528886A priority patent/JP4912309B2/ja
Priority to UAA200701971A priority patent/UA92467C2/ru
Priority to SI200531339T priority patent/SI1632232T1/sl
Priority to PCT/EP2005/054342 priority patent/WO2006024668A1/en
Priority to AT05779369T priority patent/ATE550074T1/de
Priority to AT05108086T priority patent/ATE508748T1/de
Priority to JP2007528885A priority patent/JP4922937B2/ja
Priority to EP05779369A priority patent/EP1789139B1/en
Priority to EA200700536A priority patent/EA013686B1/ru
Priority to UAA200702178A priority patent/UA92469C2/ru
Priority to US11/574,452 priority patent/US20090215804A1/en
Priority to AU2005279158A priority patent/AU2005279158C1/en
Priority to CN2005800380936A priority patent/CN101068597B/zh
Priority to HK08101831.3A priority patent/HK1112862B/xx
Priority to DK05779369.7T priority patent/DK1789139T3/da
Priority to PL05108086T priority patent/PL1632232T6/pl
Priority to DK05108086.9T priority patent/DK1632232T6/da
Priority to RS20110355A priority patent/RS51923B2/sr
Priority to KR1020077006376A priority patent/KR101276571B1/ko
Priority to AU2005279157A priority patent/AU2005279157B2/en
Priority to ES05108086T priority patent/ES2371442T7/es
Priority to BRPI0514861-8A priority patent/BRPI0514861A/pt
Priority to CA2577273A priority patent/CA2577273C/en
Priority to AP2007003934A priority patent/AP2296A/xx
Priority to NZ553322A priority patent/NZ553322A/en
Priority to SI200531539T priority patent/SI1789139T1/sl
Priority to EA200700534A priority patent/EA011036B1/ru
Priority to CA2577288A priority patent/CA2577288C/en
Priority to NZ553323A priority patent/NZ553323A/en
Priority to MX2007002594A priority patent/MX2007002594A/es
Priority to AP2007003933A priority patent/AP2487A/xx
Priority to NI200700069A priority patent/NI200700069A/es
Priority to ZA200701826A priority patent/ZA200701826B/en
Priority to NI200700068A priority patent/NI200700068A/es
Priority to IL181650A priority patent/IL181650A/en
Priority to IL181649A priority patent/IL181649A0/en
Priority to CR9032A priority patent/CR9032A/es
Priority to CR9031A priority patent/CR9031A/es
Priority to NO20071720A priority patent/NO339788B1/no
Priority to NO20071745A priority patent/NO340654B1/no
Priority to US12/168,540 priority patent/US7956063B2/en
Priority to US12/845,463 priority patent/US8101629B2/en
Priority to US13/040,465 priority patent/US20110150996A1/en
Priority to CY20111100775T priority patent/CY1112249T1/el
Priority to HK15110805.7A priority patent/HK1210029A1/xx
Priority to HUS1600061C priority patent/HUS1600061I1/hu
Priority to CY2016051C priority patent/CY2016051I1/el
Priority to FR16C1025C priority patent/FR16C1025I2/fr
Priority to CY2016050C priority patent/CY2016050I1/el
Priority to FR16C1023C priority patent/FR16C1023I2/fr
Priority to LTPA2016042C priority patent/LTC1632232I2/lt
Priority to LTPA2016043C priority patent/LTPA2016043I1/lt
Priority to HUS1600060C priority patent/HUS1600060I1/hu
Priority to NO2017063C priority patent/NO2017063I1/no
Priority to NO2017065C priority patent/NO2017065I1/no
Priority to US15/852,181 priority patent/US20180116964A1/en
Publication of MY169670A publication Critical patent/MY169670A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MYPI20043578A 2001-08-13 2004-09-02 Combinations of a pyrimidine containing nnrti with rt inhibitors MY169670A (en)

Priority Applications (69)

Application Number Priority Date Filing Date Title
CNA200580038025XA CN101056673A (zh) 2004-09-02 2005-09-02 4－[[4－[[4－(2－氰基乙烯基)－2,6－二甲基苯基]氨基]－2－嘧啶基]氨基]苄腈的盐酸盐
HRP20120499TT HRP20120499T1 (hr) 2004-09-02 2005-09-02 Fumarat cijanoetenil dimetilfenil amino pirimidinil amino benzonitrila
BRPI0514871-5A BRPI0514871A (pt) 2004-09-02 2005-09-02 cloridrato de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidi nil]amino] benzonitrila
CN201510012919.7A CN104586850A (zh) 2004-09-02 2005-09-02 4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的盐酸盐
EP05108086.9A EP1632232B3 (en) 2004-09-02 2005-09-02 Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
SG200905799-3A SG155885A1 (en) 2004-09-02 2005-09-02 Furamate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2- pyrimidinyl)amino)benzonitrile
PT05108086T PT1632232E (pt) 2004-09-02 2005-09-02 Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]- 2-pirimidinil]amino]benzonitrilo
MX2007002595A MX2007002595A (es) 2004-09-02 2005-09-02 Clorhidrato de 4-[[4-[[4- (2-cianoetenil)-2, 6-dimetilfenil] amino]-2- pirimidinil] amino] benzonitrilo.
ES05779369T ES2384715T3 (es) 2004-09-02 2005-09-02 Fumarato de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo
KR1020077006837A KR101284361B1 (ko) 2004-09-02 2005-09-02 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드
US11/219,163 US7638522B2 (en) 2001-08-13 2005-09-02 Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
PCT/EP2005/054341 WO2006024667A1 (en) 2004-09-02 2005-09-02 Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
MEP-2011-144A ME01246B (me) 2004-09-02 2005-09-02 So 4[[4-[[4-(2-cijanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrila
JP2007528886A JP4912309B2 (ja) 2004-09-02 2005-09-02 ４−［［４−［［４−（２−シアノエテニル）−２，６−ジメチルフェニル］アミノ］−２−ピリミジニル］アミノ］ベンゾニトリルの塩酸塩
UAA200701971A UA92467C2 (ru) 2004-09-02 2005-09-02 Гидрохлорид 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
SI200531339T SI1632232T1 (sl) 2004-09-02 2005-09-02 Sol 4((4((4-(2-cianoetenil)-2,6-dimetilfenil)amino)-2-pirimidinil)amino) benzonitrila
PCT/EP2005/054342 WO2006024668A1 (en) 2004-09-02 2005-09-02 Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
AT05779369T ATE550074T1 (de) 2004-09-02 2005-09-02 Fumarat aus 4-((4-((4-(2-cyanoethenyl)-2,6- dimethylphenyl amino -2-pyrimidinyl amino benzonitril
AT05108086T ATE508748T1 (de) 2004-09-02 2005-09-02 Salz von 4-ää4-ää4-(2-cyanoethenyl)-2,6- dimethylphenylüaminoü-2- pyrimidinylüaminoübenzonitril.
JP2007528885A JP4922937B2 (ja) 2004-09-02 2005-09-02 ４−（（４−（（４−（２−シアノエテニル）−２，６−ジメチルフェニル）アミノ）−２−ピリミジニル）アミノ）ベンゾニトリルのフマル酸塩
EP05779369A EP1789139B1 (en) 2004-09-02 2005-09-02 Fumarate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl amino -2-pyrimidinyl amino benzonitrile
EA200700536A EA013686B1 (ru) 2004-09-02 2005-09-02 Гидрохлорид 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
UAA200702178A UA92469C2 (en) 2004-09-02 2005-09-02 Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl amino benzonitrile
US11/574,452 US20090215804A1 (en) 2004-09-02 2005-09-02 Fumarate of 4- [[4- [[4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino] -2-pyrimidinyl]amino]benzonitrile
AU2005279158A AU2005279158C1 (en) 2004-09-02 2005-09-02 Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
CN2005800380936A CN101068597B (zh) 2004-09-02 2005-09-02 4-((4-((4-(2-氰基乙烯基)-2,6-二甲基苯基)氨基)-2-嘧啶基)氨基)苄腈的富马酸盐
HK08101831.3A HK1112862B (en) 2004-09-02 2005-09-02 Furamate of 4-((4-(4-(2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
DK05779369.7T DK1789139T3 (da) 2004-09-02 2005-09-02 Fumarat af 4-((4-((4-(2-cyanethenyl)-2,6-dimethylphenylamino-2-pyrimidinylaminobenzonitril
PL05108086T PL1632232T6 (pl) 2004-09-02 2005-09-02 Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
DK05108086.9T DK1632232T6 (da) 2004-09-02 2005-09-02 Salt af 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]¬amino]¬benzonitril
RS20110355A RS51923B2 (sr) 2004-09-02 2005-09-02 So 4[[4-[[4-(2-cijanoetenil)-2,6-dimetilfenil]amino]-2- pirimidinil]amino]benzonitrila
KR1020077006376A KR101276571B1 (ko) 2004-09-02 2005-09-02 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 푸마레이트
AU2005279157A AU2005279157B2 (en) 2004-09-02 2005-09-02 Fumarate of 4-[[4-[[4- (2-cyanoethenyl) -2,6-dimethylphenyl]amino)-2-pyrimidinyl)amino]benzonitrile
ES05108086T ES2371442T7 (es) 2004-09-02 2005-09-02 Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo
BRPI0514861-8A BRPI0514861A (pt) 2004-09-02 2005-09-02 furamato de 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino)-2-pirimidi nil)amino)benzonitrila
CA2577273A CA2577273C (en) 2004-09-02 2005-09-02 Fumarate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
AP2007003934A AP2296A (en) 2004-09-02 2005-09-02 Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile.
NZ553322A NZ553322A (en) 2004-09-02 2005-09-02 Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile, also named TMC278
SI200531539T SI1789139T1 (sl) 2004-09-02 2005-09-02 Fumarat 4-((4-((4-(2-cianoetenil)-2,6-dimetifenil amino-2-pirimidinil amino benzonitrila
EA200700534A EA011036B1 (ru) 2004-09-02 2005-09-02 Фумарат 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
CA2577288A CA2577288C (en) 2004-09-02 2005-09-02 Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
NZ553323A NZ553323A (en) 2004-09-02 2005-09-02 Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile, also named TMC278
MX2007002594A MX2007002594A (es) 2004-09-02 2005-09-02 Fumarato de 4-((4-((4- (2-cianoetenil)-2, 6-dimetilfenil) amino)-2-pirimidinil) amino) benzonitrilo.
AP2007003933A AP2487A (en) 2004-09-02 2005-09-02 Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile
NI200700069A NI200700069A (es) 2004-09-02 2007-03-01 Fumarato de 4-((4-((4- (2-cianoetenil)-2,6-dimetilfenil)amino)-2- pirimidinil) amino) benzonitrilo
ZA200701826A ZA200701826B (en) 2004-09-02 2007-03-01 Furamate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl] amino]-2-pyrimidinyl]amino]benzonitrile
NI200700068A NI200700068A (es) 2004-09-02 2007-03-01 Clorhidrato de 4-[[4-[[4-(2-cianoetenil)-2,6- dimetilfenil]amino]-2- pirimidinil]amino] benzonitrilo
IL181650A IL181650A (en) 2004-09-02 2007-03-01 Solid pharmaceutical composition comprising a pharmaceutically acceptable carrier and hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile and use thereof in the manufacture of a medicament for treating or preventing hiv infection
IL181649A IL181649A0 (en) 2004-09-02 2007-03-01 Furamate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino) benzonitrile
CR9032A CR9032A (es) 2004-09-02 2007-03-30 Fumarato de 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino-2- pirimidinil)amino)benzonitrilo
CR9031A CR9031A (es) 2004-09-02 2007-03-30 Clorhidrato de 4-((4-((4-2-cianoetenil)-2,6-dimetilfenil)amino)-2-pirimidinil)amino)benzonitrilo
NO20071720A NO339788B1 (no) 2004-09-02 2007-04-02 Fumarat av 4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]amino]-2-pyrimidinyl]amino]benzonitril
NO20071745A NO340654B1 (no) 2004-09-02 2007-04-02 Hydrokloridsaltet av 4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl]amino]-2-pyrimidinyl]amino]benzonitril
US12/168,540 US7956063B2 (en) 2001-08-13 2008-07-07 Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US12/845,463 US8101629B2 (en) 2001-08-13 2010-07-28 Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US13/040,465 US20110150996A1 (en) 2004-09-02 2011-03-04 Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino] -2-pyrimidinyl]amino]benzonitrile
CY20111100775T CY1112249T1 (el) 2004-09-02 2011-08-10 Αλας του 4-[[4-[[4-(2-κυανοαιθενυλο)-2,6-διμεθυλοφαινυλο]αμινο]-2-πυριμιδινυλο]αμινο]βενζονιτριλιου
HK15110805.7A HK1210029A1 (en) 2004-09-02 2015-11-03 Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile
HUS1600061C HUS1600061I1 (hu) 2004-09-02 2016-12-20 4[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]-2-pirimidinil]amino]benzonitril
CY2016051C CY2016051I1 (el) 2004-09-02 2016-12-20 Αλας του 4-[[4-[[4-(2-κυανοαιθενυλο)-2,6-διμεθυλοφαινυλο]αμινο]-2-πυριμιδινυλο]αμινο]βενζονιτριλιου
FR16C1025C FR16C1025I2 (fr) 2004-09-02 2016-12-20 Sel de 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
CY2016050C CY2016050I1 (el) 2004-09-02 2016-12-20 Αλας του 4-[[4-[[4-(2-κυανοαιθενυλο)-2,6-διμεθυλοφαινυλο]αμινο]-2-πυριμιδινυλο]αμινο]βενζονιτριλιου
FR16C1023C FR16C1023I2 (fr) 2004-09-02 2016-12-20 Sel de 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
LTPA2016042C LTC1632232I2 (lt) 2004-09-02 2016-12-20 4[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo druska
LTPA2016043C LTPA2016043I1 (lt) 2004-09-02 2016-12-20 4[[4-[[4-(2-Cyanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo druska
HUS1600060C HUS1600060I1 (hu) 2004-09-02 2016-12-20 4[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]-2-pirimidinil]amino]benzonitril
NO2017063C NO2017063I1 (no) 2004-09-02 2017-11-21 Kombinasjon av: - rilpivirine hydroklorid etter en terapeutisk ekvivalent form derav, - emtricitabine og - tenofovir alafenamid eller farmasøytisk akseptabelt salt derav, spesielt tenofovir alafenamidfumarat
NO2017065C NO2017065I1 (no) 2004-09-02 2017-11-21 Kombinasjon av rilpivirine-hydroklorid eller terapeutisk ekvivalent derav og tenofovir, spesielt tenofovir disproksil fumarat
US15/852,181 US20180116964A1 (en) 2004-09-02 2017-12-22 Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US49977103P 2003-09-03 2003-09-03
EP03103275 2003-09-03
EP03103319 2003-09-08
EP03103335 2003-09-10
EP03103668 2003-10-02
US50848603P 2003-10-03 2003-10-03

Publications (1)

Publication Number Publication Date
MY169670A true MY169670A (en) 2019-05-08

Family

ID=34280181

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20043578A MY169670A (en) 2001-08-13 2004-09-02 Combinations of a pyrimidine containing nnrti with rt inhibitors

Country Status (24)

Country Link
US (9) US20080200435A1 (enExample)
EP (1) EP1663240B2 (enExample)
JP (3) JP5507791B2 (enExample)
KR (1) KR20060090658A (enExample)
CN (1) CN101060844B (enExample)
AP (1) AP2109A (enExample)
AU (5) AU2004268390B2 (enExample)
BE (1) BE2015C053I2 (enExample)
CA (1) CA2537095C (enExample)
CY (5) CY2015040I2 (enExample)
FI (1) FI1663240T4 (enExample)
FR (5) FR15C0072I2 (enExample)
HR (1) HRP20150798T4 (enExample)
HU (5) HUS1500054I1 (enExample)
IL (2) IL173438A (enExample)
LT (2) LTPA2016045I1 (enExample)
LU (3) LU92853I2 (enExample)
MX (1) MXPA06002437A (enExample)
MY (1) MY169670A (enExample)
NL (2) NL300781I2 (enExample)
NO (6) NO334877B1 (enExample)
NZ (1) NZ545306A (enExample)
PL (1) PL1663240T5 (enExample)
WO (1) WO2005021001A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US7399856B2 (en) 2002-08-09 2008-07-15 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-2pyrimidinyl]amino]benzonitrile
PT1583542E (pt) 2003-01-14 2008-09-17 Gilead Sciences Inc Composições e métodos para terapia de combinação antiviral
ATE550074T1 (de) * 2004-09-02 2012-04-15 Janssen Pharmaceutica Nv Fumarat aus 4-((4-((4-(2-cyanoethenyl)-2,6- dimethylphenyl amino -2-pyrimidinyl amino benzonitril
SG155885A1 (en) * 2004-09-02 2009-10-29 Janssen Pharmaceutica Nv Furamate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2- pyrimidinyl)amino)benzonitrile
WO2006024667A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
CA2577288C (en) * 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
PT1632232E (pt) * 2004-09-02 2011-08-02 Janssen Pharmaceutica Nv Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]- 2-pirimidinil]amino]benzonitrilo
TWI457136B (zh) * 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
ATE474560T1 (de) * 2005-12-14 2010-08-15 Cipla Ltd Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit
AR059097A1 (es) * 2006-01-20 2008-03-12 Tibotec Pharm Ltd Tratamiento a largo plazo de la infeccion por vih
US9044509B2 (en) * 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
AU2008353145B2 (en) * 2008-01-03 2013-09-12 Universite D' Aix-Marseille Bitherapy and tritherapy used for treating an HIV-positive patient
MY160360A (en) * 2008-12-24 2017-02-28 Janssen Sciences Ireland Uc Implantable devices for treating hiv
ES2600878T3 (es) 2009-12-21 2017-02-13 Janssen Sciences Ireland Uc Implante removible, degradable, para la liberación prolongada de un compuesto activo
EP3351249A1 (en) 2010-01-27 2018-07-25 VIIV Healthcare Company Antiviral therapy
NZ610729A (en) 2010-11-19 2015-10-30 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
WO2012125993A1 (en) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
EP2755959B1 (en) * 2011-09-16 2018-05-16 Hetero Research Foundation Rilpivirine hydrochloride
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
CN113546052A (zh) 2015-11-09 2021-10-26 吉利德科学公司 治疗人免疫缺陷病毒的治疗组合物
MA46563B1 (fr) 2016-10-24 2024-01-31 Janssen Sciences Ireland Unlimited Co Compositions dispersibles
US20210128554A1 (en) * 2016-12-23 2021-05-06 Temple University - Of The Commonwealth System Of Higher Education Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis)
RU2019136678A (ru) * 2017-04-18 2021-05-18 Сипла Лимитед Комбинированная терапия для применения в лечении ретровирусных инфекций
WO2019021319A1 (en) * 2017-07-27 2019-01-31 Cipla Limited PHARMACEUTICAL COMPOSITIONS
WO2021104487A1 (en) 2019-11-29 2021-06-03 Aptorum Therapeutics Limited Composition including rilpivirine and use thereof for treating tumors or cancer

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182111A (en) 1987-11-17 1993-01-26 Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5368864A (en) 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
DK0489181T3 (da) 1990-07-19 1996-11-18 Otsuka Pharma Co Ltd Fast præparat
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO1993009176A2 (en) 1991-10-29 1993-05-13 Clover Consolidated, Limited Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
AU4079593A (en) 1992-05-13 1993-12-13 Wellcome Foundation Limited, The Therapeutic combinations
JPH06316524A (ja) 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
TW401303B (en) 1994-07-01 2000-08-11 Janssen Pharmaceutica Nv Anti-HIV triple combination
IT1281502B1 (it) * 1995-06-13 1998-02-18 Sardinian Antiviral Research C Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO2001021154A2 (en) 1999-09-21 2001-03-29 Rtp Pharma Inc. Surface modified particulate compositions of biologically active substances
US6743446B2 (en) 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
TWI284048B (en) 2000-01-27 2007-07-21 Zentaris Ag Compressed microparticles for dry injection
CA2404687A1 (en) 2000-03-30 2001-10-11 Nemichand B. Jain Sustained release beadlets containing stavudine
US20040115268A1 (en) 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
DE10050199A1 (de) 2000-10-11 2002-04-25 Ethicon Gmbh Flächiges Implantat mit im Ultraschall detektierbaren Elementen
PL362979A1 (en) 2000-12-11 2004-11-02 Takeda Chemical Industries, Ltd. Medicinal compositions improved in solublity in water
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
WO2003043586A2 (en) 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery
US7399856B2 (en) 2002-08-09 2008-07-15 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-2pyrimidinyl]amino]benzonitrile
WO2004022033A1 (en) 2002-09-04 2004-03-18 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
ATE361059T1 (de) 2002-11-08 2007-05-15 Glaxo Group Ltd Antivirale zusammensetzungen
MXPA05005146A (es) 2002-11-15 2005-07-22 Tibotec Pharm Ltd Indolpiridinio sustituido como compuestos antiinfecciosos.
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
EP1597237B1 (en) 2003-02-07 2016-07-27 Janssen Pharmaceutica NV Pyrimidine derivatives for the prevention of HIV infection
KR100629771B1 (ko) 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
WO2005123076A2 (en) 2004-06-08 2005-12-29 Vertex Pharmaceuticals, Inc. Pharmaceutical compositions
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
CA2577288C (en) 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
PT1632232E (pt) 2004-09-02 2011-08-02 Janssen Pharmaceutica Nv Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]- 2-pirimidinil]amino]benzonitrilo
EP2623095A1 (en) 2004-11-16 2013-08-07 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
TWI457136B (zh) 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
AR056652A1 (es) 2005-04-11 2007-10-17 Tibotec Pharm Ltd Derivados de (1,10-b dihidro-2-(aminoalquil-fenil) -5h-pirazolo (1,5-c) (1,3)benzoxazin-5-il) fenilmetanona y su uso en la fabricacion de un medicamento
CA2603851A1 (en) 2005-04-11 2006-10-19 The Board Of Trustees Of The Leland Stanford Junior Unversity Multi-layer structure having a predetermined layer pattern including an agent
US20090142401A1 (en) 2005-06-07 2009-06-04 Leah Elizabeth Appel Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
EP1912730A2 (en) 2005-07-28 2008-04-23 Isp Investments Inc. Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced
AR059097A1 (es) 2006-01-20 2008-03-12 Tibotec Pharm Ltd Tratamiento a largo plazo de la infeccion por vih
PT3366278T (pt) 2006-06-23 2024-10-21 Janssen Sciences Ireland Unlimited Co Suspensões aquosas de tmc278
US20080081064A1 (en) 2006-09-28 2008-04-03 Surmodics, Inc. Implantable Medical Device with Apertures for Delivery of Bioactive Agents
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
HRP20131128T1 (hr) 2007-07-12 2013-12-20 Janssen R&D Ireland Kristalni oblik (e) 4-[[4-[[4-(2-cijanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrila
US20090123508A1 (en) 2007-10-04 2009-05-14 Boston Scientific Scimed, Inc. Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management
EP2358198A4 (en) 2008-10-24 2012-11-14 Concert Pharmaceuticals Inc HYDROXYETHYLAMINO SULFONAMIDE DERIVATIVES

Also Published As

Publication number Publication date
CY2016049I1 (el) 2017-07-12
AU2004268390B2 (en) 2011-03-31
US20140349971A1 (en) 2014-11-27
CY2015039I2 (el) 2016-08-31
CY2015040I1 (el) 2016-08-31
NO2014030I1 (no) 2015-01-05
AU2014203484B2 (en) 2016-09-29
AU2004268390A1 (en) 2005-03-10
LU92854I2 (fr) 2015-12-21
LU92855I2 (fr) 2015-12-21
EP1663240B1 (en) 2015-04-22
JP2015044839A (ja) 2015-03-12
HUS1500053I1 (hu) 2016-03-29
AU2016210733B2 (en) 2018-11-08
CA2537095C (en) 2012-05-29
AU2011201123A1 (en) 2011-04-07
NL300781I1 (enExample) 2016-04-19
PL1663240T3 (pl) 2015-10-30
US20180228800A1 (en) 2018-08-16
AU2019200813A1 (en) 2019-02-28
HUS1500054I1 (hu) 2016-03-29
CY2016048I1 (el) 2017-07-12
CN101060844B (zh) 2012-01-04
NL300768I2 (nl) 2023-08-09
AU2016210733A1 (en) 2016-08-25
NO2014032I2 (no) 2014-12-18
FR15C0073I1 (enExample) 2015-04-12
IL173438A (en) 2012-03-29
CY2015038I1 (el) 2016-08-31
NO2014030I2 (no) 2014-12-18
FI1663240T4 (fi) 2023-04-25
FR15C0073I2 (fr) 2016-02-12
AU2011201123B2 (en) 2013-10-10
FR15C0071I1 (enExample) 2015-04-12
NO2014031I1 (no) 2015-01-05
BE2015C053I2 (enExample) 2023-12-14
US20200171027A1 (en) 2020-06-04
LTPA2016045I1 (lt) 2017-01-10
AP2109A (en) 2010-02-26
HRP20150798T4 (hr) 2023-06-09
US20100029591A1 (en) 2010-02-04
US20220008417A1 (en) 2022-01-13
FR15C0072I1 (enExample) 2015-04-12
NZ545306A (en) 2009-11-27
NO2016025I1 (enExample) 2016-12-20
CY2016048I2 (el) 2017-07-12
FR16C1022I1 (fr) 2017-02-03
CY2016049I2 (el) 2017-07-12
AU2014203484A1 (en) 2014-07-17
US20190216807A1 (en) 2019-07-18
HUS1500052I1 (hu) 2016-03-29
NO20061374L (no) 2006-03-27
US8841310B2 (en) 2014-09-23
LTC1663240I2 (lt) 2022-05-25
EP1663240A1 (en) 2006-06-07
NO2016026I1 (no) 2016-12-20
HK1092698A1 (en) 2007-02-16
NL300781I2 (enExample) 2016-04-19
US20080200435A1 (en) 2008-08-21
AP2006003551A0 (en) 2006-04-30
JP5507791B2 (ja) 2014-05-28
JP2012051915A (ja) 2012-03-15
JP2007520443A (ja) 2007-07-26
IL213104A0 (en) 2011-07-31
US20170100398A1 (en) 2017-04-13
NO2014032I1 (no) 2015-01-05
CN101060844A (zh) 2007-10-24
HUS1600059I1 (hu) 2017-02-28
FR15C0072I2 (fr) 2019-05-17
NL300768I1 (enExample) 2015-12-16
WO2005021001A1 (en) 2005-03-10
HUS1600058I1 (hu) 2017-02-28
LU92853I2 (fr) 2015-12-21
LTPA2016044I1 (lt) 2017-01-10
IL173438A0 (en) 2006-06-11
HRP20150798T1 (hr) 2015-09-11
CY2015038I2 (el) 2016-08-31
FR16C1024I1 (fr) 2017-02-03
CY2015039I1 (el) 2016-08-31
CY2015040I2 (el) 2016-08-31
KR20060090658A (ko) 2006-08-14
IL213104A (en) 2016-02-29
US20150283135A1 (en) 2015-10-08
EP1663240B2 (en) 2023-03-01
CA2537095A1 (en) 2005-03-10
NO334877B1 (no) 2014-06-23
JP5820045B2 (ja) 2015-11-24
FR15C0071I2 (fr) 2016-02-12
NO2014031I2 (no) 2014-12-18
MXPA06002437A (es) 2006-06-20
PL1663240T5 (pl) 2024-02-26

Similar Documents

Publication Publication Date Title
NO20061374L (no) Kombinasjoner av et pyrimidin inneholdende NNRTI med RT-inhibitorer
MXPA04011392A (es) Pirimidina o triazina microbicida para prevenir la tranmision sexual de vih.
IL164491A0 (en) Non nucleoside reverse transcriptase inhibitors
TW200833681A (en) Non-nucleoside reverse transcriptase inhibitors
AP2005003366A0 (en) Pyrimidine derivatives for the prevention of HIV infection.
NO20010743L (no) Antivirale indoloksoacetyl-piperazin-derivater
WO2005077050A3 (en) Hiv integrase inhibitors
GB0718575D0 (en) Nucleoside derivatives as inhibitors of viral polymerases
MY144318A (en) Methods of treating hiv infection.
GB0226930D0 (en) Chemical compounds
BR0208154A (pt) Inibidores de fosfodiesterase 3',5'-mono-fosfato guanosina cìclica
AU2003233667A1 (en) Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof
TW200738700A (en) HIV integrase inhibitors
WO2004101512A3 (en) Naphthyridine integrase inhibitors
WO2005023270A3 (en) Compositions and methods for use of antiviral drugs in the treatment of retroviral diseases resistant to nucleoside reverse transcriptase inhibitors
TW200716571A (en) Heterocyclic reverse transcriptase inhibitors
WO2003100036A3 (fr) Sulfolipides antiretroviraux extraits de spirulines, leur procede d'obtention, les compositions les contenant et leur utilisation comme inhibiteurs de la transcriptase inverse des virus vih.
BR9808564A (pt) Método de tratar um paciente tendo infecções por hiv
AR102104A2 (es) Combinaciones de una pirimidina que contienen nnrti con inhibidores de la rt
WO2008154246A8 (en) Hiv integrase inhibitors
UA85187C2 (en) 2-aminobenzoyl derivatives
AR046812A1 (es) Combinaciones de un inhibidor de la transcriptasa inversa no nucleosido (nnrti) con contenido de pirimidina con inhibidores de la transcriptasa inversa
BRPI0414027A (pt) combinações de uma pirimidina que contêm nnrti com inibidores de tr
EA200600522A1 (ru) Комбинации пиримидинсодержащего nnrti с ингибиторами обратной транскриптазы
IL155521A0 (en) Treatment of premature ejaculation